Suggested remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer after treatment with hormonal therapy such as abiraterone or enzalutamide.
Status In progress
Process STA 2018
ID number 1640

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 January 2020 - 31 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 December 2019 In progress, Referred December 5 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance